Guillermo J Ares1,2, Christie Buonpane1, Irene Helenowski3, Marleta Reynolds1, Catherine J Hunter4,5. 1. Division of Pediatric Surgery, Ann and Robert H. Lurie Children's Hospital of Chicago, 211 E Chicago Avenue, Box 63, Chicago, IL, 60611, USA. 2. Department of Surgery, University of Illinois at Chicago, 840 South Wood Street, Suite 376-CSN, Chicago, IL, 60612, USA. 3. Feinberg School of Medicine, Northwestern University, 310 East Superior Street, Morton 4-685, Chicago, IL, 60611, USA. 4. Division of Pediatric Surgery, Ann and Robert H. Lurie Children's Hospital of Chicago, 211 E Chicago Avenue, Box 63, Chicago, IL, 60611, USA. Chunter@luriechildrens.org. 5. Feinberg School of Medicine, Northwestern University, 310 East Superior Street, Morton 4-685, Chicago, IL, 60611, USA. Chunter@luriechildrens.org.
Abstract
PURPOSE: Survival of neonatal and pediatric patients undergoing extracorporeal membrane oxygenation (ECMO) ≥ 21 days has not been well described. We hypothesized that patients would have poor survival and increased long-term complications. METHODS: Retrospective, single center, review and case analysis. Tertiary-care university children's hospital including neonatal, pediatric and cardiac intensive care units. After institutional review board approval, the charts of all patients < 18 years of age undergoing ECMO for ≥ 21 continuous days were performed, and they were compared to comparative patients undergoing shorter runs. Overall survival, incidence of complications, and post-discharge recovery were recorded. RESULTS: Overall survival was 36% in patients undergoing ≥ 21 days of ECMO (N = 14). 5/8 patients with cardiopulmonary failure from acquired etiologies survived versus 0/6 patients with congenital anomalies. 1/5 survivors achieved complete recovery with no neurologic deficits. The remaining survivors suffer from multiple medical and neurodevelopmental morbidities. CONCLUSION: ECMO support for ≥ 21 days is associated with poor survival, particularly in neonates with congenital anomalies. Long-term outcomes for survivors ought to be carefully weighed and discussed with parents given the high incidence of neurologic morbidities in this population.
PURPOSE: Survival of neonatal and pediatric patients undergoing extracorporeal membrane oxygenation (ECMO) ≥ 21 days has not been well described. We hypothesized that patients would have poor survival and increased long-term complications. METHODS: Retrospective, single center, review and case analysis. Tertiary-care university children's hospital including neonatal, pediatric and cardiac intensive care units. After institutional review board approval, the charts of all patients < 18 years of age undergoing ECMO for ≥ 21 continuous days were performed, and they were compared to comparative patients undergoing shorter runs. Overall survival, incidence of complications, and post-discharge recovery were recorded. RESULTS: Overall survival was 36% in patients undergoing ≥ 21 days of ECMO (N = 14). 5/8 patients with cardiopulmonary failure from acquired etiologies survived versus 0/6 patients with congenital anomalies. 1/5 survivors achieved complete recovery with no neurologic deficits. The remaining survivors suffer from multiple medical and neurodevelopmental morbidities. CONCLUSION: ECMO support for ≥ 21 days is associated with poor survival, particularly in neonates with congenital anomalies. Long-term outcomes for survivors ought to be carefully weighed and discussed with parents given the high incidence of neurologic morbidities in this population.
Authors: Thomas V Brogan; Luke Zabrocki; Ravi R Thiagarajan; Peter T Rycus; Susan L Bratton Journal: Pediatr Crit Care Med Date: 2012-07 Impact factor: 3.624
Authors: David W Kays; Saleem Islam; Douglas S Richards; Shawn D Larson; Joy M Perkins; James L Talbert Journal: J Am Coll Surg Date: 2014-02-07 Impact factor: 6.113
Authors: Emily A Partridge; William H Peranteau; Natalie E Rintoul; Lisa M Herkert; Alan W Flake; N Scott Adzick; Holly L Hedrick Journal: J Pediatr Surg Date: 2014-11-07 Impact factor: 2.545
Authors: Ardith Z Doorenbos; Helene Starks; Erica Bourget; D Michael McMullan; Mithya Lewis-Newby; Tessa C Rue; Taryn Lindhorst; Eugene Aisenberg; Natalie Oman; J Randall Curtis; Ross Hays; Jonna D Clark; Harris P Baden; Thomas V Brogan; Jane L Di Gennaro; Robert Mazor; Joan S Roberts; Jessica Turnbull; Benjamin S Wilfond Journal: J Palliat Med Date: 2013-03-29 Impact factor: 2.947
Authors: Danielle M McCarthy; Katrina A Leone; David H Salzman; John A Vozenilek; Kenzie A Cameron Journal: Teach Learn Med Date: 2012 Impact factor: 2.414
Authors: Parthak Prodhan; Michael Stroud; Nahed El-Hassan; Sarah Peeples; Peter Rycus; Thomas V Brogan; Xinyu Tang Journal: ASAIO J Date: 2014 Jan-Feb Impact factor: 2.872